Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 45Terminated 14Recruiting 11Active not recruiting 7Withdrawn 4Not yet recruiting 2Unknown 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1Breast 1

Conditions

Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Cytarabine 102Cyclophosphamide 74fludarabine 45Idarubicin 39Decitabine 36Etoposide 35Azacitidine 34Methotrexate 31Daunorubicin 30Vincristine 28Dexamethasone 27venetoclax 25Busulfan 24Imatinib Mesylate 23Radiotherapy 20Mercaptopurine 20Granulocyte Colony-Stimulating Factor 20Dasatinib 19Peripheral Blood Stem Cell Transplantation 18Mitoxantrone 17Doxorubicin 17Immunotherapy, Adoptive 16Rituximab 15Asparaginase 15Tretinoin 14Cladribine 14fludarabine phosphate 13Prednisone 13Prednisolone 13Melphalan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Sirolimus × Other hematologic neoplasm × Clear all
NCT01428973 2024-05-09

Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens

University of Liege

Phase 2 Unknown
200 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡